Effectiveness and Safety of Ombitasvir/Paritaprevir/Ritonavir with or Without Ribavirin in Treatment of Chronic Hepatitis C Egyptian Patients on Hemodialysis

Abstract

Hepatitis C virus (HCV) is a major health problem worldwide. In 2015, the global prevalence of HCV infection was 1%. Hepatitis C virus infection is linked to CKD in several ways—some forms of renal disease are precipitated by HCV infection, and patients with end-stage kidney disease are at increased risk of acquiring HCV. HCV may exert an effect on kidney function through cryoglobulins, HCV-antibody immune complexes, or amyloid deposition. Egypt started a national treatment program intending to provide cure for Egyptian HCV-infected patients. The main aim of antiviral treatment is to eradicate the virus, which means undetectable levels of plasma HCV RNA for 12 to 24 weeks after completion of therapy. Recent development of direct acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C. Recently, the FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease, as the metabolism of these compounds is mediated predominantly by the liver. 100 patients were selected and grouped according to kidney functions to Group I (Control Group): 50 Chronic Hepatitis C virus patients with normal renal functions.